Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants

Journal of Paediatrics and Child Health

Volumn 33, Issue 4, 1997, Pages 324-328

  Ng, P C ^a,c   So, K W ^a   Fok, T F ^a   Yam, M C ^a   Wong, M Y ^b   Wong, W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Indomethacin; Patent ductus arteriosus; Preterm; Sulindac

Indexed keywords

INDOMETACIN; SULINDAC;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL;

EID: 0030870073     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.1997.tb01609.x     Document Type: Article

References (28)

1. Rennie JM, Cooke RWI. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch. Dis. Child. 1991; 66: 55-8.
2. Heymann MA. Management of PDA with prostaglandin synthetase inhibitors. In Heymann, Rudolph, The ductus arteriosus. Proceedings 75th Ross Conference Pediatric Research Columbus 1976.
3. Emmanouilides GC. Persistent patency of the ductus arteriosus in premature infants. Incidence, prenatal factors and natural history. Proceedings 75th Ross Conference Pediatric Research, Florida 1977.
4. Jones RW, Pickering D. Persistent ductus arteriosus complicating the respiratory distress syndrome. Arch. Dis. Child. 1977; 52: 274-81.
5. Stefano JL, Abbasi S, Pearlman SA, Spear ML, Esterly KL, Bhutani VK. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Am. Rev. Respir. Dis. 1991; 143: 236-9.
6. Gersony WM, Peckham GJ, Ellison RC. Effects of indomethacin in premature infants with patent ductus arteriosus. Result of a national collaborative study. J. Pediatr. 1983; 102: 895-906.
7. van Bel F, Quit GL, Schipper J, van de Bor M, Baan J. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color doppler imaging. J. Pediatr. 1991; 118: 621-6.
8. Douidar SM, Richardson J, Snodgrass WR. Role of indomethacin in ductus closure: an update evaluation. Dev. Pharmacol. Ther. 1988; 11: 196-212.
9. Yeh TF, Wilks A, Singh J, Betkerur M, Lilien L, Pildes RS. Furosemide prevents renal side effects of indomethacin therapy in preterm infants with persistent ductus arteriosus. J. Pediatr. 1982; 101: 433-7.
10. Vanhaesebrouck P, Thiery M, Leroy JG et al. Oligohydramnios, renal insufficiency and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J. Pediatr. 1988; 113: 738-43.
11. So LY, Fok TF, Sung RYT, Ho JKS. Preterm infants with patent ductus arteriosus: Treatment with an enterai preparation of indomethacin. Ann. Trop. Paediatr. 1992; 12: 403-8.
12. Alpan G, Eyal F, Vinograd I. Localized intestinal perforations after enterai administration of indomethacin in premature infants. J. Pediatr. 1985; 106: 277-81.
13. van Bel F, van Zoeren D, Schipper J, Guit GL, Baan J. Effect of indomethacin on superior mesenteric artery blood flow velocity in preterm infants. J. Pediatr. 1990; 116: 965-70.
14. Giacoia GP, Azubuike K, Taylor JR. Indomethacin and recurrent ileal perforations in a preterm infant. J. Perinatol. 1993; 13: 297-9.
15. Scholz TD, McGuinness GA. Localized intestinal perforation following intravenous indomethacin for patent ductus arteriosus. J. Pediatr. Gastroenterol. Nutr. 1988; 7: 773-5.
16. Momma K, Takao A. Increased constriction of the ductus arteriosus with combined administration of indomethacin and betamethasone in fetal rats. Pediatr. Res. 1989; 25: 69-75.
17. Davies GR, Rampton DS. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs. Aliment Pharmacol. Therap. 1991; 5: 593-8.
18. Trus T, Winthrop AL, Pipe S, Shah J, Langer JC, Lau GYP. Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J. Pediatr. Surg. 1993; 28: 1137-9.
19. Mellander M, Leheup B, Lindstrom DP. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants treated with indomethacin. J. Pediatr. 1984; 105: 138-43.
20. Sahns DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-83.
21. Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA. Efficacy and safety of indomethacin vs. ritodrine in the management of preterm labor: A randomized study. Obstet. Gynecol. 1989; 74: 567-72.
22. Zuckerman H, Reiss U, Rubinstein I. Inhibition of human preterm labor by indomethacin. Obstet. Gynecol. 1974; 44: 787-92.
23. Bunning RD, Barth WF. Sulindac. A potentially renal sparing non-steroidal anti-inflammatory drug. JAMA 1982; 248: 2864-7.
24. Ciabattoni G, Boss AH, Patrignani P. Effects of sulindac on renal and extra renal eicosanoid synthesis. Clin. Pharmacol. Ther. 1987; 41: 380-3.
25. Stillman MT, Schlesinger PA. Non-steroidal anti-inflammatory drug nephrotoxicity: Should we be concerned? Arch. Intern. Med. 1990; 150: 268-70.
26. Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D. Randomized comparative trial of indomethacin and sulindac for the treatment of refractory preterm labor. Obstet. Gynecol. 1992; 79: 223-8.
27. Caruso I, Bianchi PG. Gastroscopic evaluation of anti-inflammatory drugs. BMJ 1980; 1: 75-8.
28. Momma K, Takeuchi H. Constriction of fetal ductus arteriosus by nonsteroidal antiinflammatory drugs. Prostaglandins 1983; 26: 631-43.